![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
|
Phase I Pilot Study of NY-ESO-1 Peptide Vaccine and Sargramostim (GM-CSF) in Patients With Stage II, III, or IV Soft Tissue Sarcoma Expressing NY-ESO-1 or LAGE Antigen
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma
Basic Trial Information
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
Phase
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
Type
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
Status
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
Age
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
Sponsor
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
Protocol IDs
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif)
Phase I
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif)
Treatment
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif)
Closed
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif)
18 and over
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif)
NCI
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif)
CPMC-IRB-13578 LUDWIG-LUD00-024, NCI-G01-2035, NCT00027911
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
|
Objectives - Determine the safety and tolerability of NY-ESO-1 peptide vaccine and sargramostim (GM-CSF) in patients with stage II, III, or IV soft tissue sarcoma expressing NY-ESO-1 or LAGE antigen.
- Determine the immunologic profile (NY-ESO-1 antibody, CD8+ cells, and delayed-type hypersensitivity) in patients treated with this regimen.
- Determine tumor responses in patients treated with this regimen.
Entry Criteria Disease Characteristics:
- Histologically confirmed high-risk stage II, III, or IV soft tissue
sarcoma expressing NY-ESO-1 or LAGE antigen (including, but not limited to,
synovial
sarcoma)
- HLA-A2 allele for NY-ESO-1 peptides
- Declined, failed, or completed standard therapy
- CNS metastases allowed if treated and stable
Prior/Concurrent Therapy:
Biologic therapy: - No prior bone marrow or peripheral blood stem cell
transplantation
- At least 4 weeks since prior immunotherapy
Chemotherapy: - At least 4 weeks since prior chemotherapy (6 weeks for
nitrosoureas)
- No concurrent chemotherapy
Endocrine therapy: - No concurrent steroids except topical or inhaled steroids
- Concurrent noncytotoxic anticancer hormonal therapy allowed
(e.g., hormones for breast or prostate cancer)
Radiotherapy: - At least 4 weeks since prior radiotherapy
Surgery: - At least 4 weeks since prior surgery
Other: - At least 4 weeks since prior participation in any other
clinical trial involving another investigational agent
- No concurrent antihistamines
- No concurrent non-steroidal anti-inflammatory drugs except low
doses for prevention of an acute cardiovascular event or pain
control
- No concurrent immunosuppressive agents
- Concurrent noncytotoxic anticancer therapy allowed
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - Hemoglobin at least 9.0 g/dL
- Lymphocyte count at least 500/mm3
- Platelet count at least 100,000/mm3
- No bleeding disorders
Hepatic: - Bilirubin no greater than 2 mg/dL
- Hepatitis B and C negative
Renal: - Creatinine no greater than 1.8 mg/dL
Cardiovascular: - No New York Heart Association class III or IV heart
disease
Other: - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- No other serious illness (e.g., serious infection requiring
antibiotics)
- No immunodeficiency disease
- No psychiatric or addictive disorders that would preclude
study
Expected Enrollment A total of 15 patients will be accrued for this study within 12 months. Outline Patients receive NY-ESO-1 peptide vaccine intradermally once every 2
weeks for a total of 6 vaccinations. Patients also receive sargramostim
(GM-CSF) subcutaneously once daily beginning 2 days before every vaccination
and continuing for 5 days. Treatment continues in the absence of disease
progression or unacceptable toxicity.
Trial Contact Information
Trial Lead Organizations Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center ![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) | Kyriakos Papadopoulos, MD, Protocol chair(Contact information may not be current) | ![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) | | ![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) |
Registry Information | ![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) | Official Title | | A Pilot Study of NY-ESO-1 Immunization in Patients with NY-ESO-1/LAGE Antigen Expressing Cancer | ![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) | Trial Start Date | | 2001-04-02 | ![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) | Registered in ClinicalTrials.gov | | NCT00027911 | ![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) | Date Submitted to PDQ | | 2001-10-24 | ![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) | Information Last Verified | | 2004-04-08 | ![](https://webarchive.library.unt.edu/eot2008/20081019110736im_/http://www.cancer.gov/images/spacer.gif) | NCI Grant/Contract Number | | P30-CA13696 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
![](images/spacer.gif) |